OPKO Health’s ModeX Therapeutics Begins Clinical Trial of Tetraspecific Antibody for Treatment of B-cell Lymphomas
ModeX Therapeutics, an OPKO Health company, announced the dosing of patients in a Phase 1 trial for MDX2003, a first-in-class tetraspecific antibody targeting B-cell lymphomas. The MDX-2003-101 study is designed to evaluate safety, tolerability, and immune activity of the drug, which targets CD19, CD20, CD3, and CD28 to optimize T-cell killing.
Key figures
- Drug Name
- MDX2003
- Phase Of Trial
- Phase 1
- Clinical trial id
- NCT07249905
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.